View Older Stories View More Recent Stories

Feb 27, 2019 07:30AM Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events
Feb 21, 2019 07:30AM Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th
Feb 20, 2019 09:00AM Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference
Feb 6, 2019 08:00AM Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
Jan 16, 2019 08:00AM Fibrocell to Present at Phacilitate Leaders World 2019
Jan 15, 2019 07:30AM Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis
Jan 2, 2019 07:30AM Intrexon Announces Presentations at Upcoming Investor Conferences
Dec 20, 2018 07:34AM Intrexon (XON) and Merck KGaA Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
Dec 20, 2018 07:30AM Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
Dec 18, 2018 07:31AM Intrexon (XON), AquaBounty (AQB) Secures Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production
Dec 18, 2018 07:30AM Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production
Dec 11, 2018 08:00AM Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
Nov 28, 2018 07:30AM Oxitec Transitioning Friendly™ Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs
Nov 13, 2018 08:00AM Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
Nov 8, 2018 04:10PM Intrexon Announces Third Quarter 2018 Financial Results
Nov 8, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights
Nov 1, 2018 07:30AM Intrexon to Announce Third Quarter 2018 Financial Results on November 8th
Oct 29, 2018 07:32AM Intrexon (XON) Subsidiary ActoBio Therapeutics Inc. Reports First Patient Dosing in Phase Ib/IIa Clinical Study of AG019 for Treatment of Type 1 Diabetes
Oct 29, 2018 07:30AM ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
Oct 25, 2018 08:15AM Fibrocell Science (FCSC) Receives FDA Guidance on Phase 3 Clinical Trial Design for FCX-007
Oct 25, 2018 08:00AM Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
Oct 24, 2018 07:30AM Intrexon Announces the Formation of Bioinformatics Hub in Munich
Oct 18, 2018 08:43AM Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes
Oct 9, 2018 07:09AM Ziopharm Oncology (ZIOP), Precigen (XON) Enter New License Agreement
Oct 9, 2018 07:00AM Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
Sep 26, 2018 08:00AM Fibrocell to Present at Upcoming Industry and Investor Conferences
Sep 25, 2018 08:06AM Fibrocell Science (FCSC) Secures $1.4M FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Sep 25, 2018 08:00AM Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Sep 24, 2018 07:31AM Intrexon (XON) Reports Advances in Production of Medical Cannabis
Sep 24, 2018 07:30AM Intrexon Announces Advances in Production of Medical Cannabis
Sep 12, 2018 06:30AM Intrexon Announces Transfer of Stock Listing to Nasdaq
Sep 10, 2018 03:30PM Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets
Sep 5, 2018 08:07AM Fibrocell Science (FCSC) Reports FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Sep 5, 2018 08:00AM Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Sep 5, 2018 08:00AM Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Aug 29, 2018 08:00AM Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference
Aug 9, 2018 04:57PM Intrexon Business Update and Conference Call
Aug 9, 2018 08:00AM Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
Aug 3, 2018 07:30AM Intrexon to Present at the Jefferies 2018 Global Industrials Conference
Aug 2, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights
Aug 2, 2018 07:30AM Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th
Jun 19, 2018 09:53AM Intrexon's (XON) Oxitec Partners with Bill & Melinda Gates Foundation for Malaria
Jun 19, 2018 09:44AM Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
May 29, 2018 09:24AM Fibrocell Science (FCSC) Prices 2.04M Share Common Offering at $2.85/Sh
May 29, 2018 09:20AM Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
May 29, 2018 08:00AM Isolation and Recombinant Expression of Key Enzyme for Opioid Production
May 24, 2018 08:56AM Fibrocell Announces One-for-Five Reverse Stock Split
May 24, 2018 07:00AM Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly™ Mosquitoes Platform
May 23, 2018 08:11AM The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
May 23, 2018 08:11AM The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
View More Recent Stories View Older Stories